189 related articles for article (PubMed ID: 32204699)
1. Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma.
Kesh K; Mendez R; Abdelrahman L; Banerjee S; Banerjee S
Microb Cell Fact; 2020 Mar; 19(1):75. PubMed ID: 32204699
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiome and type 2 diabetes: where we are and where to go?
Sharma S; Tripathi P
J Nutr Biochem; 2019 Jan; 63():101-108. PubMed ID: 30366260
[TBL] [Abstract][Full Text] [Related]
3. Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans.
Doumatey AP; Adeyemo A; Zhou J; Lei L; Adebamowo SN; Adebamowo C; Rotimi CN
Front Cell Infect Microbiol; 2020; 10():63. PubMed ID: 32158702
[TBL] [Abstract][Full Text] [Related]
4. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Geller LT; Barzily-Rokni M; Danino T; Jonas OH; Shental N; Nejman D; Gavert N; Zwang Y; Cooper ZA; Shee K; Thaiss CA; Reuben A; Livny J; Avraham R; Frederick DT; Ligorio M; Chatman K; Johnston SE; Mosher CM; Brandis A; Fuks G; Gurbatri C; Gopalakrishnan V; Kim M; Hurd MW; Katz M; Fleming J; Maitra A; Smith DA; Skalak M; Bu J; Michaud M; Trauger SA; Barshack I; Golan T; Sandbank J; Flaherty KT; Mandinova A; Garrett WS; Thayer SP; Ferrone CR; Huttenhower C; Bhatia SN; Gevers D; Wargo JA; Golub TR; Straussman R
Science; 2017 Sep; 357(6356):1156-1160. PubMed ID: 28912244
[TBL] [Abstract][Full Text] [Related]
5. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-37 sensitize the elderly type 2 diabetic patients to insulin therapy through suppressing the gut microbiota dysbiosis.
Li T; Li H; Li W; Chen S; Feng T; Jiao W; Wu C; Dong J; Li Y; Li S; Feng M; Wei X
Mol Immunol; 2019 Aug; 112():322-329. PubMed ID: 31238287
[TBL] [Abstract][Full Text] [Related]
7. Streptozotocin-induced hyperglycemia alters the cecal metabolome and exacerbates antibiotic-induced dysbiosis.
Wurster JI; Peterson RL; Brown CE; Penumutchu S; Guzior DV; Neugebauer K; Sano WH; Sebastian MM; Quinn RA; Belenky P
Cell Rep; 2021 Dec; 37(11):110113. PubMed ID: 34910917
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine.
Hayashi T; Ding Q; Kuwahata T; Maeda K; Miyazaki Y; Matsubara S; Obara T; Natsugoe S; Takao S
Cancer Sci; 2012 May; 103(5):889-96. PubMed ID: 22320450
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
11. The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine.
Chen SM; Chieng WW; Huang SW; Hsu LJ; Jan MS
Sci Rep; 2020 Nov; 10(1):20319. PubMed ID: 33230218
[TBL] [Abstract][Full Text] [Related]
12. Obesity enriches for tumor protective microbial metabolites and treatment refractory cells to confer therapy resistance in PDAC.
Kesh K; Mendez R; Mateo-Victoriano B; Garrido VT; Durden B; Gupta VK; Oliveras Reyes A; Merchant N; Datta J; Banerjee S; Banerjee S
Gut Microbes; 2022; 14(1):2096328. PubMed ID: 35816618
[TBL] [Abstract][Full Text] [Related]
13. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycemic Effect of Ginsenoside Rg5 Mediated Partly by Modulating Gut Microbiota Dysbiosis in Diabetic db/db Mice.
Wei Y; Yang H; Zhu C; Deng J; Fan D
J Agric Food Chem; 2020 May; 68(18):5107-5117. PubMed ID: 32307991
[TBL] [Abstract][Full Text] [Related]
15. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
16. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.
Liang C; Shi S; Meng Q; Liang D; Ji S; Zhang B; Qin Y; Xu J; Ni Q; Yu X
Exp Mol Med; 2017 Dec; 49(12):e406. PubMed ID: 29611542
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
[TBL] [Abstract][Full Text] [Related]
18. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism.
Grasset E; Puel A; Charpentier J; Collet X; Christensen JE; Tercé F; Burcelin R
Cell Metab; 2017 May; 25(5):1075-1090.e5. PubMed ID: 28467926
[TBL] [Abstract][Full Text] [Related]
19. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C
Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130
[TBL] [Abstract][Full Text] [Related]
20. Considering gut microbiota in treatment of type 2 diabetes mellitus.
Adeshirlarijaney A; Gewirtz AT
Gut Microbes; 2020 May; 11(3):253-264. PubMed ID: 32005089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
